BioXcel Therapeutics, Inc.(BTAI)Earnings, Financials & Key Ratios
BTAI•NASDAQ
$1.30
$3M mkt cap·Price updated May 6, 2026
AboutBioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.Show more
- Revenue$2M+64.2%
- EBITDA-$67M+61.0%
- Net Income-$60M+66.7%
- EPS (Diluted)-23.51+76.1%
- Gross Margin5.43%-37.6%
- EBITDA Margin-2953.93%+76.2%
- Operating Margin-2967.56%+76.2%
- Net Margin-2630.14%+79.7%
- Interest Coverage-4.44+65.6%
BTAI Key Insights
BioXcel Therapeutics, Inc. (BTAI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Shares diluted 39.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BTAI Price & Volume
BioXcel Therapeutics, Inc. (BTAI) stock price & volume — 10-year historical chart
Loading chart...
BTAI Growth Metrics
BioXcel Therapeutics, Inc. (BTAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-66.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM71.83%
Return on Capital
10 Years-111.02%
5 Years-114.24%
3 Years-150.78%
Last Year-215.05%
BTAI Peer Comparison
BioXcel Therapeutics, Inc. (BTAI) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 CORT | 5.6B | 52.15 | 63.60 | 12.79% | 6.23% | 7.5% | 0.01 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 |
Compare BTAI vs Peers
BioXcel Therapeutics, Inc. (BTAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BTAI Income Statement
BioXcel Therapeutics, Inc. (BTAI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 375K | 1.38M | 2.27M | 752K |
| Revenue Growth % | - | - | - | - | - | - | - | 268% | 64.2% | -66.96% |
| Cost of Goods Sold | 0 | 1K | 17K | 156K | 0 | 297K | 20K | 1.26M | 2.14M | 1.04M |
| COGS % of Revenue | - | - | - | - | - | - | 5.33% | 91.3% | 94.57% | - |
| Gross Profit | 0▲ 0% | -1K▲ 0% | -17K▼ 1600.0% | -156K▼ 817.6% | 0▲ 100.0% | -297K▲ 0% | 355K▲ 219.5% | 120K▼ 66.2% | 123K▲ 2.5% | -287K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | 94.67% | 8.7% | 5.43% | -38.16% |
| Gross Profit Growth % | - | - | -1600% | -817.65% | 100% | - | 219.53% | -66.2% | 2.5% | - |
| Operating Expenses | 2.12M | 4.54M | 19.96M | 33.6M | 82.3M | 105.6M | 160M | 171.9M | 67.37M | 50.09M |
| OpEx % of Revenue | - | - | - | - | - | - | 42666.67% | 12456.67% | 2972.99% | - |
| Selling, General & Admin | 721K | 1.85M | 5.4M | 7.8M | 24.65M | 54.01M | 68.76M | 83.41M | 34.49M | 20.78M |
| SG&A % of Revenue | - | - | - | - | - | - | 18336.27% | 6044.42% | 1522.15% | - |
| Research & Development | 1.4M | 2.69M | 14.56M | 25.8M | 58.54M | 51.59M | 91.24M | 84.33M | 30.43M | 29.27M |
| R&D % of Revenue | - | - | - | - | - | - | 24330.4% | 6110.58% | 1343.12% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -888K | 0 | 0 | 4.16M | 2.44M | 32K |
| Operating Income | -2.12M▲ 0% | -4.54M▼ 114.0% | -19.96M▼ 340.0% | -33.6M▼ 68.3% | -82.3M▼ 144.9% | -105.89M▼ 28.7% | -159.65M▼ 50.8% | -171.78M▼ 7.6% | -67.25M▲ 60.9% | -50.37M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | -42572% | -12447.97% | -2967.56% | -6698.4% |
| Operating Income Growth % | - | -114.01% | -339.98% | -68.32% | -144.92% | -28.67% | -50.76% | -7.6% | 60.85% | - |
| EBITDA | 0 | -4.54M | -19.95M | -33.45M | -82.11M | -105.6M | -159.32M | -171.46M | -66.94M | -50.07M |
| EBITDA Margin % | - | - | - | - | - | - | -42484.8% | -12424.93% | -2953.93% | -6658.11% |
| EBITDA Growth % | - | - | -339.7% | -67.69% | -145.5% | -28.61% | -50.87% | -7.62% | 60.96% | 34.19% |
| D&A (Non-Cash Add-back) | 2.12M | 1K | 17K | 156K | 188K | 297K | 327K | 318K | 309K | 303K |
| EBIT | -2.12M | -4.54M | -19.27M | -32.97M | -82.3M | -107.29M | -157.54M | -165.74M | -44.47M | -51.59M |
| Net Interest Income | 0 | -2K | 0 | 633K | 128K | -36K | -5.68M | -7.67M | -12.53M | -10.74M |
| Interest Income | 0 | 0 | 0 | 633K | 155K | 4K | 2.53M | 5.65M | 2.6M | 1.89M |
| Interest Expense | 0 | 2K | 0 | 0 | 27K | 40K | 8.21M | 13.31M | 15.13M | 12.63M |
| Other Income/Expense | 0 | -2K | 692K | 633K | 128K | -1.4M | -6.11M | -7.27M | 7.65M | -17.84M |
| Pretax Income | -2.12M▲ 0% | -4.54M▼ 114.1% | -19.27M▼ 324.5% | -32.97M▼ 71.1% | -82.17M▼ 149.2% | -107.29M▼ 30.6% | -165.76M▼ 54.5% | -179.05M▼ 8.0% | -59.6M▲ 66.7% | -68.21M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | -44201.87% | -12974.86% | -2630.14% | -9070.61% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -362K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0.34% | 0% | 0% | 0% | 0% |
| Net Income | -2.12M▲ 0% | -4.54M▼ 114.1% | -19.27M▼ 324.5% | -32.34M▼ 67.8% | -82.17M▼ 154.1% | -106.93M▼ 30.1% | -165.76M▼ 55.0% | -179.05M▼ 8.0% | -59.6M▲ 66.7% | -68.21M▲ 0% |
| Net Margin % | - | - | - | - | - | - | -44201.87% | -12974.86% | -2630.14% | -9070.61% |
| Net Income Growth % | - | -114.1% | -324.54% | -67.8% | -154.12% | -30.14% | -55.01% | -8.02% | 66.71% | 3.92% |
| Net Income (Continuing) | -2.12M | -4.54M | -19.27M | -32.97M | -82.17M | -106.93M | -165.76M | -179.05M | -59.6M | -68.21M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.06▲ 0% | -4.41▼ 114.1% | -21.16▼ 379.8% | -32.38▼ 53.0% | -60.63▼ 87.2% | -64.87▼ 7.0% | -94.67▼ 45.9% | -98.35▼ 3.9% | -23.51▲ 76.1% | -4.80▲ 0% |
| EPS Growth % | - | -114.08% | -379.82% | -53.02% | -87.25% | -6.99% | -45.94% | -3.89% | 76.1% | 71.83% |
| EPS (Basic) | -2.06 | -4.41 | -21.16 | -32.38 | -60.63 | -64.87 | -94.67 | -98.35 | -23.51 | - |
| Diluted Shares Outstanding | 1.03M | 1.03M | 910.72K | 1.02M | 1.36M | 1.65M | 1.75M | 1.82M | 2.54M | 14.2M |
| Basic Shares Outstanding | 1.03M | 1.03M | 910.72K | 1.02M | 1.36M | 1.65M | 1.75M | 1.82M | 2.54M | 14.2M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BTAI Balance Sheet
BioXcel Therapeutics, Inc. (BTAI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2K | 890K | 43.17M | 34.11M | 217.06M | 236.81M | 202.87M | 72.14M | 37.39M | 44.4M |
| Cash & Short-Term Investments | 0 | 887K | 42.56M | 32.43M | 213.12M | 232.97M | 193.72M | 65.22M | 29.85M | 37.32M |
| Cash Only | 0 | 887K | 42.56M | 32.43M | 213.12M | 232.97M | 193.72M | 65.22M | 29.85M | 37.32M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 115K | 0 | 0 | 0 | 248K | 71K | 131K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | 241.39 | 18.78 | 21.1 | 17.96 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 1.99M | 1.99M | 679K | 459K |
| Days Inventory Outstanding | - | - | - | - | - | - | 36.23K | 576.76 | 115.65 | 200.77 |
| Other Current Assets | 0 | 0 | 0 | 0 | 984K | 956K | 3.84M | 2.08M | 1.44M | 934K |
| Total Non-Current Assets | 5K | 465K | 378K | 2.29M | 2.87M | 2.63M | 2.98M | 1.56M | 944K | 389K |
| Property, Plant & Equipment | 5K | 4K | 327K | 2.23M | 2.78M | 2.54M | 2.06M | 1.47M | 857K | 389K |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.18x | 0.94x | 2.64x | 1.21x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 461K | 51K | 51K | 87K | 86K | 925K | 87K | 87K | 174K |
| Total Assets | 7K▲ 0% | 1.35M▲ 19257.1% | 43.55M▲ 3113.9% | 36.39M▼ 16.4% | 219.94M▲ 504.4% | 239.44M▲ 8.9% | 205.85M▼ 14.0% | 73.7M▼ 64.2% | 38.34M▼ 48.0% | 44.79M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x | 0.02x | 0.06x | 0.02x |
| Asset Growth % | - | 19257.14% | 3113.95% | -16.43% | 504.35% | 8.87% | -14.03% | -64.2% | -47.98% | -170.11% |
| Total Current Liabilities | 331K | 2.34M | 4.66M | 8.47M | 11.84M | 16.67M | 32.9M | 27.27M | 22.23M | 37.8M |
| Accounts Payable | 279K | 444K | 1.6M | 4.95M | 3.98M | 4.68M | 10.23M | 13.65M | 15.99M | 16.28M |
| Days Payables Outstanding | - | 162.06K | 34.44K | 11.59K | - | 5.75K | 186.66K | 3.96K | 2.72K | 5.66K |
| Short-Term Debt | 0 | 371K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.98M |
| Deferred Revenue (Current) | 0 | 0 | 0 | -164K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 2.04M | 2.07M | 3.97M | 6.46M | 163K | 142K | 4.41M |
| Current Ratio | 0.01x | 0.38x | 9.26x | 4.03x | 18.33x | 14.21x | 6.17x | 2.65x | 1.68x | 1.68x |
| Quick Ratio | 0.01x | 0.38x | 9.26x | 4.03x | 18.33x | 14.21x | 6.11x | 2.57x | 1.65x | 1.65x |
| Cash Conversion Cycle | - | - | - | - | - | - | -150.19K | -3.36K | -2.59K | -5.44K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 1.03M | 1.4M | 1.1M | 96.18M | 102.94M | 109.21M | 95.91M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 93.05M | 100.6M | 102.51M | 92.3M |
| Capital Lease Obligations | 0 | 0 | 0 | 1.03M | 1.4M | 1.1M | 786K | 440K | 65K | 65K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 2.34M | 1.91M | 6.63M | 16.12M |
| Total Liabilities | 331K | 2.34M | 4.66M | 9.5M | 13.24M | 17.77M | 129.08M | 130.21M | 131.44M | 133.71M |
| Total Debt | 0 | 371K | 0 | 1.03M | 1.64M | 1.4M | 94.16M | 101.38M | 102.95M | 109.29M |
| Net Debt | 0 | -516K | -42.56M | -31.4M | -211.48M | -231.57M | -99.57M | 36.16M | 73.09M | 71.97M |
| Debt / Equity | - | - | - | 0.04x | 0.01x | 0.01x | 1.23x | - | - | -1.23x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.18x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.44x |
| Interest Coverage | - | -2268.50x | - | - | -3048.04x | -2647.38x | -19.44x | -12.90x | -4.44x | -4.09x |
| Total Equity | -324K▲ 0% | -982K▼ 203.1% | 38.89M▲ 4060.2% | 26.89M▼ 30.8% | 206.7M▲ 668.5% | 221.67M▲ 7.2% | 76.78M▼ 65.4% | -56.51M▼ 173.6% | -93.1M▼ 64.8% | -88.92M▲ 0% |
| Equity Growth % | - | -203.09% | 4060.18% | -30.84% | 668.53% | 7.24% | -65.36% | -173.6% | -64.76% | -138.11% |
| Book Value per Share | -0.31 | -0.95 | 42.70 | 26.42 | 152.52 | 134.48 | 43.85 | -31.04 | -36.73 | -6.26 |
| Total Shareholders' Equity | -324K | -982K | 38.89M | 26.89M | 206.7M | 221.67M | 76.78M | -56.51M | -93.1M | -88.92M |
| Common Stock | 0 | 10K | 16K | 18K | 24K | 28K | 28K | 30K | 49K | 73K |
| Retained Earnings | 0 | -4.45M | -23.72M | -56.69M | -138.86M | -245.79M | -411.55M | -590.6M | -650.2M | -707.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -1K | -18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BTAI Cash Flow Statement
BioXcel Therapeutics, Inc. (BTAI) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.29M | -2.2M | -13.51M | -27.28M | -66.35M | -82.15M | -135.34M | -155.01M | -72.03M | -72.03M |
| Operating CF Margin % | - | - | - | - | - | - | -36090.93% | -11232.32% | -3178.6% | - |
| Operating CF Growth % | - | -69.71% | -515.16% | -101.94% | -143.22% | -23.82% | -64.74% | -14.53% | 53.53% | 107.6% |
| Net Income | -2.12M | -4.54M | -19.27M | -32.97M | -82.17M | -106.93M | -165.76M | -179.05M | -59.6M | -68.21M |
| Depreciation & Amortization | 0 | 1K | 17K | 156K | 188K | 297K | 327K | 318K | 309K | 303K |
| Stock-Based Compensation | 671K | 1.61M | 3.08M | 3.14M | 14.61M | 19.45M | 17.34M | 18.61M | 6.16M | 1.74M |
| Deferred Taxes | 0 | 0 | 0 | -3.45M | -14.99M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 671K | 1.61M | 3.12M | 3.45M | 14.99M | 46K | 2.35M | 3.1M | -12.86M | 12.29M |
| Working Capital Changes | 155K | 736K | 2.66M | 2.39M | 1.02M | 4.98M | 10.4M | 2.02M | -6.03M | -4.33M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -248K | 177K | -60K | 3K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -1.99M | -6K | 1.31M | 1.07M |
| Change in Payables | 156K | 737K | 3.2M | 3.58M | 3.03M | 4.85M | 13.03M | -3.22M | -4.33M | -4.37M |
| Cash from Investing | -4K | 0 | -340K | -870K | -316K | -445K | -139K | -20K | 0 | 0 |
| Capital Expenditures | -4K | 0 | -340K | -870K | -316K | -445K | -139K | -20K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | 37.07% | 1.45% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -340K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.3M | 3.08M | 55.53M | 18.01M | 247.36M | 102.45M | 96.24M | 26.52M | 36.66M | 55.15M |
| Debt Issued (Net) | 0 | 438K | -371K | 0 | 0 | 0 | 98.6M | 0 | -2.5M | -2.5M |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 3.14M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -9.02M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.3M | 584K | -615K | 201K | 598K | 1.45M | -2.36M | -510K | -528K | -869K |
| Net Change in Cash | 0▲ 0% | 887K▲ 0% | 41.68M▲ 4598.8% | -10.14M▼ 124.3% | 180.69M▲ 1882.2% | 19.85M▼ 89.0% | -39.24M▼ 297.7% | -128.5M▼ 227.5% | -35.37M▲ 72.5% | -3.07M▲ 0% |
| Free Cash Flow | -1.3M▲ 0% | -2.2M▼ 69.2% | -13.85M▼ 530.6% | -28.15M▼ 103.3% | -66.67M▼ 136.8% | -82.6M▼ 23.9% | -135.48M▼ 64.0% | -155.03M▼ 14.4% | -72.03M▲ 53.5% | -58.21M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | -36128% | -11233.77% | -3178.6% | -7741.22% |
| FCF Growth % | - | -69.18% | -530.65% | -103.26% | -136.82% | -23.9% | -64.02% | -14.43% | 53.54% | 30.76% |
| FCF per Share | -1.26 | -2.13 | -15.21 | -27.65 | -49.19 | -50.11 | -77.38 | -85.15 | -28.41 | -28.41 |
| FCF Conversion (FCF/Net Income) | 0.61x | 0.48x | 0.70x | 0.84x | 0.81x | 0.77x | 0.82x | 0.87x | 1.21x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 2.7M | 7.55M | 7.97M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BTAI Key Ratios
BioXcel Therapeutics, Inc. (BTAI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -101.67% | -98.31% | -70.35% | -49.93% | -111.08% | -1766.94% | - | 71.83% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | 220.83% |
| Gross Margin | - | - | - | - | - | 94.67% | 8.7% | 5.43% | -38.16% |
| Net Margin | - | - | - | - | - | -44201.87% | -12974.86% | -2630.14% | -9070.61% |
| Debt / Equity | - | - | 0.04x | 0.01x | 0.01x | 1.23x | - | - | -1.23x |
| Interest Coverage | -2268.50x | - | - | -3048.04x | -2647.38x | -19.44x | -12.90x | -4.44x | -4.09x |
| FCF Conversion | 0.48x | 0.70x | 0.84x | 0.81x | 0.77x | 0.82x | 0.87x | 1.21x | 0.85x |
| Revenue Growth | - | - | - | - | - | - | 268% | 64.2% | -66.96% |
BTAI Frequently Asked Questions
BioXcel Therapeutics, Inc. (BTAI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioXcel Therapeutics, Inc. (BTAI) reported $0.8M in revenue for fiscal year 2024.
BioXcel Therapeutics, Inc. (BTAI) grew revenue by 64.2% over the past year. This is strong growth.
BioXcel Therapeutics, Inc. (BTAI) reported a net loss of $68.2M for fiscal year 2024.
Dividend & Returns
BioXcel Therapeutics, Inc. (BTAI) had negative free cash flow of $58.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More BTAI
BioXcel Therapeutics, Inc. (BTAI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates